Canine Gastric Tumor Study Guide

Overview and Clinical Importance

Gastric tumors in dogs represent less than 1% of all canine malignancies but carry significant clinical importance due to their late presentation, high metastatic rate, and poor prognosis. Understanding the various tumor types, their breed predispositions, diagnostic approaches, and treatment options is essential for the NAVLE examination and clinical practice. Most gastric tumors in dogs are malignant, with adenocarcinoma being the most common (42-72% of cases), followed by lymphoma, leiomyosarcoma, and gastrointestinal stromal tumors (GISTs).

Epidemiology and Etiology

General Characteristics

Gastric tumors most commonly affect older dogs (median age 8-10 years), with a male predilection (male-to-female ratio of 2-2.5:1). The etiology remains largely unknown, although chronic nitrosamine administration has been associated with gastric carcinoma development in experimental settings. A strong genetic component is suspected given the significant breed predispositions.

Breed Predispositions

Classification of Canine Gastric Tumors

1. Gastric Adenocarcinoma

Gastric adenocarcinoma is the most common malignant gastric tumor in dogs, accounting for 42-72% of gastric neoplasms. These tumors arise from the glandular epithelium of the gastric mucosa.

Anatomic Location

• Most common location: Pyloric antrum and lesser curvature (lower two-thirds of stomach)
• Three anatomic presentations: Scirrhous (linitis plastica - firm, non-distensible), plaque-like with central ulceration, or raised polypoid lesions

Histologic Classification

WHO Classification divides carcinomas based on cellular differentiation:

• Papillary: Finger-like projections of epithelial cells
• Tubular: Gland-forming pattern
• Mucinous: Greater than 50% extracellular mucin
• Signet ring cell: Poorly cohesive cells with intracytoplasmic mucin (common in Chow Chows and Belgian Shepherds)

Metastatic Behavior

Metastatic rate: 74-77% at time of diagnosis. Common metastatic sites include: gastric lymph nodes, omentum, liver, peritoneum, lungs, duodenum, pancreas, spleen, esophagus, and adrenal glands.

2. Leiomyoma and Leiomyosarcoma

These smooth muscle tumors arise from the muscularis layer of the gastric wall. Leiomyoma is benign and typically presents as a discrete, solitary mass often found in the gastric cardia. Leiomyosarcoma is malignant, invasive, and has a metastatic rate of approximately 16-30%.

Key Distinguishing Features

3. Gastrointestinal Stromal Tumor (GIST)

GISTs are mesenchymal neoplasms arising from the interstitial cells of Cajal (the "pacemaker cells" of the GI tract). Previously, many GISTs were misclassified as leiomyosarcomas. The hallmark of GIST diagnosis is positive immunohistochemical staining for c-KIT (CD117) and DOG1.

Key Characteristics

• Location: More common in cecum and large intestine than stomach in dogs
• c-KIT mutations: Present in 60-70% of cases, most commonly in exon 11
• Metastatic rate: Up to 30%; typically grows slowly
• Treatment: Surgery plus tyrosine kinase inhibitors (toceranib phosphate or imatinib)

Differentiating GIST from Leiomyosarcoma

Exam Focus: Differentiating GIST from leiomyosarcoma requires immunohistochemistry since they appear identical on routine H&E staining. Remember: c-KIT positive = GIST, c-KIT negative + desmin/SMA positive = leiomyosarcoma. This distinction is clinically important because GISTs may respond to tyrosine kinase inhibitors!

4. Gastric Lymphoma

Gastric lymphoma in dogs is usually part of alimentary lymphoma or multicentric disease. It is predominantly high-grade and large cell type with aggressive clinical behavior. The main treatment is systemic chemotherapy, not surgery.

• Presentation: May be solitary or diffuse; often transmural thickening
• Treatment: Multi-agent chemotherapy (CHOP-based protocols)
• Prognosis: High-grade GI lymphoma has poor prognosis; MST 62-77 days with treatment
• Exception: Low-grade (small cell) T-cell intestinal lymphoma has better prognosis with chlorambucil and prednisone (MST 628 days)

Clinical Signs and Presentation

Clinical signs of gastric tumors are often nonspecific and insidious, developing over weeks to months. This contributes to the late-stage diagnosis commonly seen with these tumors. The average duration of clinical signs before diagnosis is 2-3 weeks to several months.

Common Clinical Signs

Diagnostic Approach

Laboratory Findings

Laboratory findings in dogs with gastric tumors are often nonspecific:

• CBC: Microcytic hypochromic anemia (chronic blood loss); may have leukocytosis
• Chemistry: Hypoproteinemia/hypoalbuminemia; hypoglycemia with leiomyosarcoma
• Fecal occult blood: Often positive; indicates GI bleeding

Diagnostic Imaging

Ultrasonography

Ultrasonography is the most useful first-line imaging modality for evaluating suspected gastric tumors and can identify masses in 69-80% of cases.

Computed Tomography (CT)

CT has superior sensitivity (92%) compared to ultrasound (69%) for detecting gastric tumors and better characterizes extent of disease and metastasis.

Treatment Options

Surgical Treatment

Surgical excision is the gold standard treatment for nonmetastatic, non-lymphomatous gastric tumors.

Chemotherapy

Prognosis and Survival Times